ImmunityBio provides N-803 BLA update with May 23 PDUFA, reports NSCLC OS data, and notes S1800D closure

ImmunityBio, Inc.

BLA for N-803+BCG in BCG-unresponsive NMIBC with CIS; PDUFA date May 23, 2023; approval uncertain.
QUILT 3.055 NSCLC pooled analysis (N=86) shows median OS 13.9 months vs historical 6-7.5 months.
SWOG/NCI S1800D study (N-803+pembrolizumab) closed early for not meeting 60% disease control at 12 weeks.
Company exploring partnering for N-803 intravesical commercialization and potential financing from Executive Chairman.
Board appointed Cheryl L. Cohen as Lead Independent Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.